Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 2
1997 2
1999 1
2000 1
2003 2
2004 2
2007 1
2008 3
2011 2
2012 3
2014 1
2015 1
2016 1
2017 3
2018 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

25 results
Results by year
Filters applied: . Clear all
Page 1
Differential indication of lipoprotein apheresis during pregnancy.
Klingel R, Göhlen B, Schwarting A, Himmelsbach F, Straube R. Klingel R, et al. Among authors: himmelsbach f. Ther Apher Dial. 2003 Jun;7(3):359-64. doi: 10.1046/j.1526-0968.2003.00066.x. Ther Apher Dial. 2003. PMID: 12924613 Review.
SGLT6 - A pharmacological target for the treatment of obesity?
Baader-Pagler T, Eckhardt M, Himmelsbach F, Sauer A, Stierstorfer BE, Hamilton BS. Baader-Pagler T, et al. Among authors: himmelsbach f. Adipocyte. 2018;7(4):277-284. doi: 10.1080/21623945.2018.1516098. Epub 2018 Oct 11. Adipocyte. 2018. PMID: 30161013 Free PMC article.
Efficacy of lipid reduction with DALI and MONET.
Ramlow W, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Pham J, Kozik-Jaromin J. Ramlow W, et al. Among authors: himmelsbach f. Atheroscler Suppl. 2017 Nov;30:217-224. doi: 10.1016/j.atherosclerosissup.2017.05.035. Epub 2017 Jun 1. Atheroscler Suppl. 2017. PMID: 29096841
Discovery of BI 135585, an in vivo efficacious oxazinanone-based 11β hydroxysteroid dehydrogenase type 1 inhibitor.
Zhuang L, Tice CM, Xu Z, Zhao W, Cacatian S, Ye YJ, Singh SB, Lindblom P, McKeever BM, Krosky PM, Zhao Y, Lala D, Kruk BA, Meng S, Howard L, Johnson JA, Bukhtiyarov Y, Panemangalore R, Guo J, Guo R, Himmelsbach F, Hamilton B, Schuler-Metz A, Schauerte H, Gregg R, McGeehan GM, Leftheris K, Claremon DA. Zhuang L, et al. Among authors: himmelsbach f. Bioorg Med Chem. 2017 Jul 15;25(14):3649-3657. doi: 10.1016/j.bmc.2017.04.033. Epub 2017 Apr 29. Bioorg Med Chem. 2017. PMID: 28528082
Safety aspects of lipidapheresis using DALI and MONET - Multicenter observational study.
Kozik-Jaromin J, Röseler E, Heigl F, Spitthöver R, Ringel J, Schmitz G, Heinzler R, Abdul-Rahman N, Leistikow F, Himmelsbach F, Schettler V, Uhlenbusch-Körwer I, Ramlow W. Kozik-Jaromin J, et al. Among authors: himmelsbach f. Atheroscler Suppl. 2017 Nov;30:225-231. doi: 10.1016/j.atherosclerosissup.2017.05.036. Atheroscler Suppl. 2017. PMID: 29096842
3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: a class of potent DPP-4 inhibitors.
Eckhardt M, Hauel N, Himmelsbach F, Langkopf E, Nar H, Mark M, Tadayyon M, Thomas L, Guth B, Lotz R. Eckhardt M, et al. Among authors: himmelsbach f. Bioorg Med Chem Lett. 2008 Jun 1;18(11):3158-62. doi: 10.1016/j.bmcl.2008.04.075. Epub 2008 May 1. Bioorg Med Chem Lett. 2008. PMID: 18485703
Pharmacological characterization of the selective 11β-hydroxysteroid dehydrogenase 1 inhibitor, BI 135585, a clinical candidate for the treatment of type 2 diabetes.
Hamilton BS, Himmelsbach F, Nar H, Schuler-Metz A, Krosky P, Guo J, Guo R, Meng S, Zhao Y, Lala DS, Zhuang L, Claremon DA, McGeehan GM. Hamilton BS, et al. Among authors: himmelsbach f. Eur J Pharmacol. 2015 Jan 5;746:50-5. doi: 10.1016/j.ejphar.2014.10.053. Epub 2014 Nov 8. Eur J Pharmacol. 2015. PMID: 25445047
25 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page